• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肿瘤扩散、分级及生长模式作为膀胱癌形态学预测参数的价值。对1987年TNM分类的批判性修订。

The value of tumour spread, grading and growth pattern as morphological predictive parameters in bladder carcinoma. A critical revision of the 1987 TNM classification.

作者信息

Angulo J C, Lopez J I, Flores N, Toledo J D

出版信息

J Cancer Res Clin Oncol. 1993;119(10):578-93. doi: 10.1007/BF01372721.

DOI:10.1007/BF01372721
PMID:8335677
Abstract

A group of 343 patients with bladder carcinomas was uniformly staged, both clinico-radiologically and pathologically. In accordance with pathological staging, they were treated from 1983 to 1990 and follow-up was closed on January 1992. No systemic chemotherapy regime was used. The present study was designed to assess the value of classical morphological parameters (tumour extension, histological subtype, grade and growth pattern) in the prediction of prognosis, and also to evaluate the adequacy of the current TNM classification (4th edition, 1987) of bladder cancer. The initial tumour stage appears the most useful criterion in the prediction of prognosis. Nevertheless, survival analysis confirms the necessity to modify the present TNM classification for routine clinical practice. In fact, stage III proves to be heterogeneous, and the difference in survival between categories pT3a and pT3b is even more statistically significant (log-rank P < 0.01) than the difference between pT2 and pT3 as a whole (log-rank P < 0.02). Consequently, invasion of the muscular layer should be reclassified into a common stage II, equivalent to the B category in the ABCD system. Moreover, stage IV is also heterogeneous in terms of survival. Despite the overall life-expectancy being rather poor for a patient with bladder carcinoma, three subsets with different prognosis (log-rank P < 0.001) can be identified: pT4N0M0; pTxN1-3M0; pTxNyM1, where x and y represent any number. Therefore, we believe that various subgroups should be distinguished in a future edition of the TNM classification. Current treatment modalities, involving the role of systemic chemotherapy and aimed at bladder preservation, make such innovations even more convenient for a new edition of the TNM classification of bladder cancer. Apart from tumour staging, several microscopic morphological parameters are valuable in distinguishing patients with different prognosis. Pure transitional-cell histology, papillar growth, and low grade, are favourable data. In fact, tumour grade, although somewhat subjective, is a factor of major prognostic importance. Pauwels' distinction of intermedium grade 2 into 2A and 2B is also helpful in the assessment of a population of "intermediate" prognosis. Similarly, with regard to superficial tumours, the division of infiltration levels of subepithelial connective tissue into "superficial" or "deep into the muscularis mucosae", is also relevant, even after stratification by grade.

摘要

一组343例膀胱癌患者进行了统一的临床放射学和病理学分期。根据病理分期,于1983年至1990年对他们进行治疗,并于1992年1月结束随访。未使用全身化疗方案。本研究旨在评估经典形态学参数(肿瘤浸润范围、组织学亚型、分级和生长方式)在预测预后中的价值,同时评估当前膀胱癌TNM分类(1987年第4版)的适用性。初始肿瘤分期似乎是预测预后最有用的标准。然而,生存分析证实有必要对当前的TNM分类进行修改以用于常规临床实践。实际上,III期被证明是异质性的,pT3a和pT3b亚组之间的生存差异在统计学上甚至比pT2和pT3整体之间的差异更显著(对数秩检验P<0.01,而pT2和pT3整体之间差异对数秩检验P<0.02)。因此,肌层浸润应重新分类为一个共同的II期,等同于ABCD系统中的B期。此外,IV期在生存方面也是异质性的。尽管膀胱癌患者的总体预期寿命较差,但可以识别出三个预后不同的亚组(对数秩检验P<0.001):pT4N0M0;pTxN1 - 3M0;pTxNyM1,其中x和y代表任意数字。因此,我们认为在TNM分类的未来版本中应区分不同的亚组。当前涉及全身化疗作用且旨在保留膀胱的治疗模式,使得对膀胱癌TNM分类的新版本进行此类创新更加便利。除了肿瘤分期外,一些微观形态学参数在区分不同预后的患者方面也很有价值。单纯移行细胞组织学、乳头状生长和低分级是有利的数据。实际上,肿瘤分级虽然有些主观,但却是一个重要的预后因素。Pauwels将中级2级分为2A和2B也有助于评估“中等”预后的人群。同样,对于浅表肿瘤,即使按分级分层后,将上皮下结缔组织浸润水平分为“浅表”或“深入黏膜肌层”也是有意义的。

相似文献

1
The value of tumour spread, grading and growth pattern as morphological predictive parameters in bladder carcinoma. A critical revision of the 1987 TNM classification.肿瘤扩散、分级及生长模式作为膀胱癌形态学预测参数的价值。对1987年TNM分类的批判性修订。
J Cancer Res Clin Oncol. 1993;119(10):578-93. doi: 10.1007/BF01372721.
2
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
3
Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?当前的生存预测工具在治疗骨转移后的骨骼相关事件时有用吗?
Clin Orthop Relat Res. 2024 Sep 1;482(9):1710-1721. doi: 10.1097/CORR.0000000000003030. Epub 2024 Mar 22.
4
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.卡莫司汀植入剂与替莫唑胺治疗新诊断的高级别胶质瘤的有效性和成本效益:一项系统评价与经济学评估
Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450.
5
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
6
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
7
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
8
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
9
Optimal primary surgical treatment for advanced epithelial ovarian cancer.晚期上皮性卵巢癌的最佳初次手术治疗
Cochrane Database Syst Rev. 2011 Aug 10;2011(8):CD007565. doi: 10.1002/14651858.CD007565.pub2.
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.

引用本文的文献

1
Hot Spots in Urogenital Basic Cancer Research and Clinics.泌尿生殖系统基础癌症研究与临床热点
Cancers (Basel). 2025 Mar 31;17(7):1173. doi: 10.3390/cancers17071173.
2
Advances in Urological Cancer in 2022, from Basic Approaches to Clinical Management.2022年泌尿生殖系统癌症进展:从基础研究到临床管理
Cancers (Basel). 2023 Feb 23;15(5):1422. doi: 10.3390/cancers15051422.
3
(Pro)renin Receptor Is a Novel Independent Prognostic Marker in Invasive Urothelial Carcinoma of the Bladder.(前)肾素受体是膀胱浸润性尿路上皮癌中一种新型独立的预后标志物。

本文引用的文献

1
Infiltrating carcinoma of the bladder; relation of depth of penetration of the bladder wall to incidence of local extension and metastases.膀胱浸润性癌;膀胱壁浸润深度与局部扩展及转移发生率的关系。
J Urol. 1946 Apr;55:366-72. doi: 10.1016/S0022-5347(17)69924-5.
2
Infiltrating carcinoma of the bladder; curability by total cystectomy.膀胱浸润性癌;全膀胱切除术的可治愈性。
J Urol. 1948 Jul;60(1):107-18. doi: 10.1016/S0022-5347(17)69206-1.
3
Carcinoma of the bladder: influence of depth of infiltration on the 5-year results following complete extirpation of the primary growth.
Cancers (Basel). 2021 Nov 11;13(22):5642. doi: 10.3390/cancers13225642.
4
Long-Term Experience with Hyperthermic Chemotherapy (HIVEC) Using Mitomycin-C in Patients with Non-Muscle Invasive Bladder Cancer in Spain.西班牙非肌层浸润性膀胱癌患者使用丝裂霉素进行热化疗(HIVEC)的长期经验
J Clin Med. 2021 Oct 30;10(21):5105. doi: 10.3390/jcm10215105.
5
Insights into Urological Cancer.泌尿系统癌症洞察
Cancers (Basel). 2021 Jan 8;13(2):204. doi: 10.3390/cancers13020204.
6
Differences in Pathologic Results of Repeat Transurethral Resection of Bladder Tumor (TURBT) according to Institution Performing the Initial TURBT: Comparative Analyses between Referred and Nonreferred Group.根据初始 TURBT 执行机构,重复经尿道膀胱肿瘤切除术(TURBT)的病理结果差异:转诊组与非转诊组的比较分析。
Biomed Res Int. 2018 Sep 6;2018:9432606. doi: 10.1155/2018/9432606. eCollection 2018.
7
Detection of Intratumor Heterogeneity in Modern Pathology: A Multisite Tumor Sampling Perspective.现代病理学中肿瘤内异质性的检测:多部位肿瘤采样视角
Front Med (Lausanne). 2017 Mar 6;4:25. doi: 10.3389/fmed.2017.00025. eCollection 2017.
8
DNA Methylation and Urological Cancer, a Step Towards Personalized Medicine: Current and Future Prospects.DNA甲基化与泌尿系统癌症:迈向个性化医疗的一步——现状与未来展望
Mol Diagn Ther. 2016 Dec;20(6):531-549. doi: 10.1007/s40291-016-0231-2.
9
Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion.尾加压素II受体通过调节细胞运动/侵袭来决定膀胱癌的预后。
J Exp Clin Cancer Res. 2014 Jun 3;33(1):48. doi: 10.1186/1756-9966-33-48.
10
Growth pattern in superficial urothelial bladder carcinomas. Histological review and clinical relevance.浅表性膀胱癌的生长模式。组织学回顾与临床相关性。
Int Urol Nephrol. 2009 Dec;41(4):847-54. doi: 10.1007/s11255-009-9537-x. Epub 2009 Mar 12.
膀胱癌:原发肿瘤完整切除后浸润深度对5年结果的影响。
J Urol. 1952 May;67(5):672-80. doi: 10.1016/S0022-5347(17)68403-9.
4
A STUDY OF 365 CASES OF INFILTRATING BLADDER CANCER: RELATION OF CERTAIN PATHOLOGICAL CHARACTERISTICS TO PROGNOSIS AFTER EXTIRPATION.365例浸润性膀胱癌的研究:某些病理特征与切除术后预后的关系
J Urol. 1964 Dec;92:668-78. doi: 10.1016/S0022-5347(17)64029-1.
5
NATURAL HISTORY AND CLINICAL BEHAVIOR OF IN SITU CARCINOMA OF THE HUMAN URINARY BLADDER.人膀胱原位癌的自然史与临床行为
Cancer. 1964 Dec;17:1533-45. doi: 10.1002/1097-0142(196412)17:12<1533::aid-cncr2820171205>3.0.co;2-7.
6
Statistical aspects of the analysis of data from retrospective studies of disease.疾病回顾性研究数据的统计分析方面
J Natl Cancer Inst. 1959 Apr;22(4):719-48.
7
Potentialities of bladder epithelium.膀胱上皮的潜能
J Urol. 1954 Jun;71(6):705-14. doi: 10.1016/S0022-5347(17)67849-2.
8
The relation of the preoperative estimate to the pathologic demonstration of the extent of vesical neoplasms.膀胱肿瘤范围的术前评估与病理显示之间的关系。
J Urol. 1952 Oct;68(4):714-23. doi: 10.1016/S0022-5347(17)68271-5.
9
TNM (1978) in bladder cancer: use and abuse.膀胱癌中的TNM分期(1978年):应用与滥用
Br J Urol. 1980 Dec;52(6):500-5. doi: 10.1111/j.1464-410x.1980.tb03100.x.
10
The heterogeneity of invasive bladder carcinoma and different responses to treatment.浸润性膀胱癌的异质性及对治疗的不同反应。
J Urol. 1980 May;123(5):644-52. doi: 10.1016/s0022-5347(17)56075-9.